T-siHER2-NP™ for treating drug resistant HER2+ breast cancer:

Nanoparticle loaded with trastuzumab (HER2 targeting agent) and siRNA to knock down HER2

Cellular specific uptake; efficient HER2 knockdown, and treatment specificity of T-siHER2-NP™

A. Specific uptake to HER2+ cells over low-HER2 cells; B. Knock down >80% of HER2 protein; and C. Specific killing of HER2+ cancer over low HER2 cells

T-siHER2-NP™ can inhibit two resistant HER2+ tumor

– HCC1954 tumors were resistant to Trastuzumab and taxane (A), but responded to T-siHER2-NP™ (B).

– 60% HER2 knock down in tumors after 1 dose (inset of B).

C. BT474-TR tumors were resistant to Trastuzumab, but responded to T-siHER2-NP

Publications:

Gu, S., Hu, Z., Ngamcherdtrakul, W., Castro, D.J., Morry, J., Reda, M., Gray, J.W., Yantasee, W. Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget, 2016, 7(12): 14727-14741. | View PDF

Ngamcherdtrakul, W., Morry, J., Gu, S., Castro, D. J., Goodyear, S. M., Sangvanich, T., Reda, M. M., Lee, R., Mihelic, S. A., Beckman, B. L., Hu, Z., Gray, J. W., Yantasee, W. Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer. Advanced Functional Materials, 2015, 25(18), 2646-2659. View Cover | View PDF